RETRACTED: Travoprost-loaded PEGylated solid lipid nanoparticle-laden silicone contact lens for managing glaucoma

Carboplatin Niosomal Nanoplatform for Potentiated Chemotherapy

“…PEG functions as a reducing agent of lamellarity and a stabilizing agent, which restricts nanoparticle aggregation. [36][37][38] After PEGylation, the size and PDI of nanoparticles decreased (195.3 § 9.3 and 226.0 § 10.6 nm; 0.162 § 0.007 and 0.228 § 0.02 for PEG-NS and PEG-NS-CB, respectively)., and this could be due to the function of PEG as a reducing agent of lamellarity and a stabilizing agent. 37,38 PEG causes an increased intensity of lateral repulsion to the lipid bilayers and a curve in the lipid bilayer, resulting in a reduction in the vesicle size.…”

“…37 These features make PEGylated niosomes smaller than that of non-PEGylated niosome. In addition, PEG is a stabilizing agent 38 and inhibits the nanoparticle aggregation, 39 resulting in a lower PDI value for PEGylated niosomes, compared to non-PEGylated ones. 40 These results were in agreement with the results of Haroun et al 40 study, where PEGylated niosomes (134 § 2.1 nm, 0.277), compared to non-PEGylated niosomes (278 § 2.8 nm, 0.411), were smaller and had lower PDI values.…”

“…As the results demonstrated, PEG-NS and PEG-NS-CB, compared to NS and NS-CB, were more homogenous and monodisperse owing to the stabilizing function of PEG. 38…”

Nanoparticles for the treatment of glaucoma-associated neuroinflammation

“…Due to their optimal size for the penetration of ocular barriers, NPs usually do not impose eye irritation, thereby limiting the frequency of drug administration as well as maintaining sustained drug release [ 161 ]. Lately, there has been an increased emergence of reports on NPs (e.g., polymeric [ 175 , 176 ] and lipid-based [ 177 , 178 ]) for drug-eluting contact lenses and corneal implants. Such commercialized medical devices provide a sustained and burst drug release with high bioavailability to the anterior and posterior segments of the eye, which may improve patient adherence as compared to eye drop medications [ 179 ].…”

Retraction Note: Ofloxacin‑Loaded Niosome‑Laden Contact Lens: Improved Properties of Biomaterial for Ocular Drug Delivery

“…The authors were asked for raw data, but were unable to supply credible materials. Additionally, the article contains an overlap with a previously published article by different authors [1]. The Editor-in-Chief, therefore, no longer has confidence in the integrity of data in this article.…”